Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy

Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-ind...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Daniel J. Serie, Julia E. Crook, Brian M. Necela, Bianca C. Axenfeld, Travis J. Dockter, Gerardo Colon-Otero, Edith A. Perez, E. Aubrey Thompson, Nadine Norton
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2017-05-01
Colecção:Journal of Cardiovascular Development and Disease
Assuntos:
dilated cardiomyopathy
modifying variants
GWAS
LVEF
OBSCN
breast cancer
trastuzumab
doxorubicin
Acesso em linha:http://www.mdpi.com/2308-3425/4/2/6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados